Poster Session 3 – Thursday, December 9, 2021: 7:00 am – 8:30 am CT
   
  Detection/Diagnosis - Imaging and Screening: Breast Imaging - Mammography etc.
P3-01-09 MRI in the pre-operative workup of breast cancer patients
Bayard S, Fasano G, Chen Y, Marti J, Simmons R, Swistel A, Drotman M, Davis M, Newman L. Weill Cornell, New York, NY; Henry Ford Health System, Detroit, MI.
P3-01-11 A clinical study indicates that 3D mammography shows no improvement over 2D mammography in cancer detection rates and biopsy-derived positive predictive value among BI-RADS 4 populations
Ezeana CF, Puppala M, Wang L, Chang JC, Wong STC. Houston Methodist Research Institute/Houston Methodist Cancer Center, Houston, TX; Houston Methodist Cancer Center, Houston, TX.
P3-01-12 The impact of COVID-19 on diagnosis of recurrent breast cancer
Di Cosimo S, Depretto C, Miceli R, Baili P, Ljevar S, Sant M, Ferranti C, Folli S, Gennaro M, de Braud FG, Vernieri C, De Santis MC, Lozza L, Vingiani A, Pruneri G, Apolone G, Marchianò A, Scaperrotta GP. Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
P3-01-13 Comparing portable and clinical ultrasound systems using 3D printed breast phantom inserts
Valdez D, Fukui J, Wolfgruber T, Leong L, Maskarinec G, Shepherd J. University of Hawaii Cancer Center, Honolulu, HI.
P3-01-14 A model incorporating axillary tail position on mammography for preoperative prediction of non-sentinel lymph node metastasis in patients with initial cN+ breast cancer after neoadjuvant chemotherapy
Wang K, Zhu T, Zhang T. Guangdong General Hospital, Guangzhou, China.
P3-01-15 Significant discordance between clinical and pathological staging in early stage HER2+ and triple negative breast cancers treated with upfront surgery
Sidda A, Biglow L, Abdallah M, Manu G, Gress T, Tirona M. Marshall University - Edwards Comprehensive Cancer Center, Huntington, WV.
P3-01-16 Screening for genetic risk at the time of mammography
Shames J, Alnabulsi D, Trachtenberg O, Lopez A. Sidney Kimmel Cancer Center at Jefferson Health, Philadephia, PA.
P3-01-17 MRI study of a novel paramagnetic seed for clinically occult breast tumor localization
Thiruchelvam P, Leff D, Upadhyay N. Imperial College, London, United Kingdom.
P3-01-18 Withdrawn
P3-01-25 Assessing the impact of preoperative breast MRI on time to treatment for invasive lobular carcinoma
Wright MD, Dempster MS, ElSherif A, Cocco D, Valente SA, Li H, Kruse ML. Cleveland Clinic, Cleveland, OH.
P3-01-26 Mammographic density in relation to breast cancer risk factors among Chinese women
Koka H, Tian Y, Lu D, Yu K, Li E-N, Guo C, Zhu B, Guida JL, Chan A, Hu N, Lu N, Gierach G, Li J, Yang XR. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD; Volpara Health Technologies Ltd, Wellington, New Zealand.
   
  Detection/Diagnosis - Imaging and Screening: Molecular, Functional, and Novel Imaging
P3-02-01 Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma
Hath DK, Konovalova N, Molina-Vega J, Newitt DC, Lawhn-Heath C, Ray KM, Joe BN, Heditsian D, Brain S, I-SPY 2 TRIAL Imaging Working Group, I-SPY 2 TRIAL Consortium, Chien AJ, Esserman LJ, Hylton NM, Mukhtar RA, and Jones EF. University of California, San Francisco, San Francisco, CA.
P3-02-02 FES-dedicated breast PET uptake in early-stage ER+ breast cancers
Jones EF, Hathi DK, Molina-Vega J, Newitt DC, Lawhn-Heath C, Ray KM, Joe BN, Heditsian D, Brain S, Mukhtar RA, Chien AJ, Rugo HS, I-SPY 2 TRIAL Consortium, I-SPY 2 TRIAL Imaging Working Group, Esserman LJ, Hylton NM. University of California, San Francisco, San Francisco, CA.
P3-02-03 Quantitative molecular breast imaging for early prediction of neoadjuvant systemic therapy response in locally advanced breast cancer patients
Patel MM, Adrada BE, Lopez B, Candelaria RP, Sun J, Boge M, Mohamed RM, Elshafeey N, Whitman G, Le-Petross HT, Santiago L, Scoggins ME, Lane D, Moseley T, Zylberman G, Saddler J, Leung JWT, Yang WT, Valero V, Kappadath SC, Rauch GM. The University of Texas MD Anderson Cancer Center, Houston, TX.
P3-02-04 Prediction of breast cancer response to neoadjuvant chemotherapy in different biological breast cancer subtypes using diffuse optical tomography
Altoe ML, Kalinsky KM, Guo H, Hibshoosh H, Tejada M, Crew KD, Accordino MK, Trivedi MS, Marone A, Kim HY, Hielscher AH, Hershman DL. New York University, New York, NY; Columbia University Irving Medical Center, New York, NY.
P3-02-05 Assessment of repeatability and uptake quantification of 68GaNOTA-anti-HER2 sdAb PET/CT in patients with locally advanced or metastatic breast cancer
Gondry O, Xavier C, Waelput W, Al Dabssi O, Vanhoeij M, Aspeslagh S, Joris S, Fontaine C, Verfaillie G, De Grève J, Glorieus K, Luyten I, Vandenbroucke F, Bourgeois S, Raes L, Thyparambil S, Devoogdt N, Vaneycken I, Cousaert J, Caveliers V, Everaert H, Lahoutte T, Keyaerts M. Nuclear Medicine Department, UZ Brussel and In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium; Department of Pathology, UZ Brussel, Brussels, Belgium; Nuclear Medicine Department, UZ Brussel, Brussels, Belgium; Department of Oncological Surgery, UZ Brussel, Brussels, Belgium; Department of Medical Oncology, UZ Brussel, Brussels, Belgium; Department of Radiology, UZ Brussel, Brussels, Belgium; mProbe, Rockville, MD.
P3-02-06 A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer
Alhuseinalkhudhur A, Lindman H, Liss P, Sundin T, Frejd FY, Hartman J, Iyer V, Lubberink M, Velikyan I, Sörensen J. Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden; Clinical Research and Development Unit, Uppsala University Hospital, Uppsala, Sweden; Department of Oncology and Pathology, Karolinska Institute, Uppsala, Sweden; Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
P3-02-07 Assessing the variability of cardiac elasticity imaging to identify subclinical therapy related cardiac degradation in premenopausal women with breast cancer
Miller CE, Jordan JH, Douglas E, Ansley K, Thomas A, Weis J. Wake Forest School of Medicine, Biomedical Engineering, Winston-Salem, NC; Virginia Commonwealth University, Biomedical Engineering, Richmond, VA; Wake Forest Baptist Health Medical Center, Winston-Salem, NC; Wake Forest Baptist Health Medical Center Hematology and Oncology, and Comprehensive Cancer Center, Winston-Salem, NC; Wake Forest School of Medicine Biomedical Engineering, Wake Forest Baptist Health Medical Center Comprehensive Cancer Center, Winston-Salem, NC.
P3-02-08 Diagnosis, navigation, treatment: A versatile biocompatible and biodegradable mesoporous silica platform of NIR II fluorescence imaging for early diagnosis, breast cancer precisely surgery, and radiosensitization
Wei M, Wang P, Zhang G. Xiamen University, Xiamen, China; Haixi Institutes, Chinese Academy of Sciences, Xiamen, China.
P3-02-09 Three timepoint pharmacokinetic modeling to incorporate within standard of care MRI breast exams
DiCarlo JC, Jarrett AM, Kazerouni AS, Virostko J, Sorace AG, Slavkova KP, Patt D, Goodgame BW, Avery S, Yankeelov TE. The University of Texas at Austin, Austin, TX; University of Washington, Seattle, WA; University of Alabama at Birmingham, Birmingham, AL; Texas Oncology, Austin, TX; Austin Radiological Association, Austin, TX.
P3-02-10 Balixafortide-functionalized down-conversion NIR-IIb nanoparticles for lymph node-invaded breast cancer detection
Zhu Y-Y, Zhang Y-Q, Wang Z, Chen M, Zhang G-J. Department of Breast-Thyroid-Surgery and Cancer Center, Xiang’an Hospital of Xiamen University, Xiamen, China; ChangJiang Scholar's Laboratory, Medical College, Shantou University, Shantou, China; Clinical Central Research Core, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen, China.
P3-02-11 Towards a new standard for staging: A comparative study of [18F]FES PET/CT vs [18F]FDG PET/CT in patients with clinical stage II/III and locoregional recurrent estrogen receptor positive breast cancer
Iqbal R, Bonjer EC, van Zweeden A, Mammatas LH, Teunissen JJM, Booij J, Diepenhorst GMP, Schijf L, van der Velde S, Duvivier K, Barbé E, Oprea-Lager DE, Menke-van der Houven van Oordt CW. Amsterdam UMC - location VUmc, Amsterdam, Netherlands; Amstelland Hospital, Amstelveen, Netherlands; Reinier de Graaf Gasthuis, Delft, Netherlands; Amsterdam UMC - location AMC, Amsterdam, Netherlands; Flevo Hospital, Almere, Netherlands.
   
  Detection/Diagnosis - Imaging and Screening: Radiology - Tumor Monitoring
P3-03-01 Functional tumor volume at 3 and 6-week MRI as an indicator of patients with inferior outcome after neoadjuvant chemotherapy
Natsuko Onishi, Jessica E Gibbs, Wen Li, David C Newitt, Elissa R Price, Barbara LeStage, William F Symmans, Angela M DeMichele, Christina Yau, the I-SPY 2 TRIAL Imaging Working Group, the I-SPY 2 TRIAL Consortium, Laura J Esserman and Nola M Hylton. University of California, San Francisco, San Francisco, CA;I-SPY 2 Advocacy Group, San Francisco, CA;MD Anderson Cancer Center, Houston, TX;University of Pennsylvania, Philadelphia, PA.
P3-03-02 Diffusion-weighted MRI for prediction of pathologic complete response in HER2- breast cancer treated with pembrolizumab plus neoadjuvant chemotherapy
Li W, Le NN, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, I-SPY 2 TRIAL Imaging Working Group, I-SPY 2 TRIAL Consortium, Esserman LJ, Hylton NM. UCSF, San Francisco, CA;university of Washington, Seattle, WA;I-SPY 2 Advocacy Group, San Francisco, CA.
P3-03-03 Quantitative multiparametric MRI predicts response to neoadjuvant therapy in the community setting
Virostko J, Sorace AG, Slavkova KP, Kazerouni AS, Jarrett AM, DiCarlo JC, Woodard S, Avery S, Goodgame BW, Patt D, Yankeelov TE. University of Texas at Austin, Dell Medical School, Austin, TX;University of Alabama at Birmingham, Birmingham, AL;University of Washington, Seattle, WA;Austin Radiological Association, Austin, TX;Texas Oncology, Austin, TX.
P3-03-04 Challenges of achieving high image quality on breast MRI for quantitative measurements in the I-SPY 2 TRIAL
Bareng TJ, Gibbs JE, Onishi N, Newitt DC, LeStage B, I-SPY 2 TRIAL Imaging Working Group, I-SPY 2 TRIAL Coordinators, HyltonNM. University of California, San Francisco, San Francisco, CA;Dana-Farber Cancer Institute, Boston, MA.
P3-03-05 The budget impact of the DiviTum®TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer
Guzauskas GF, Carlson JJ, Dann RA, Ramsey SD. University of Washington, Seattle, WA;Biovica, Bost, MA;Fred Hutchinson Cancer Research Center, Seattle, WA.
P3-03-06 Prediction of response to neoadjuvant systemic therapy in triple negative breast cancer using baseline tumor MRI characteristics and imaging patterns of response
Guirguis MS, Adrada BE, Candelaria RP, Sun J, Whitman GJ, Yang WT, Boge M, Mohamed RW, Elshafeey NA, Lane DL, Le-Petross H, Leung JWT, Santiago L, Scoggins ME, Spak DA, Patel MP, Perez F, Wei P, Tripathy D, White J, Ravenberg E, Huo L, Litton J, Arun B, Valero V, Thompson A, Moulder S, Yam C, Rauch GM. University of Texas MD Anderson Cancer Center, Houston, TX;Baylor College of Medicine, Houston, TX;Eli Lily and Company, Indianapolis, IN.
P3-03-07 Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL
Christofferson A, Price E, Mukhtar RA, Basu A, Esserman L, Chien AJ. University of California, San Francisco, San Francisco, CA.
P3-03-08 Background parenchymal enhancement as an imaging biomarker in neoadjuvant endocrine therapy for DCIS
Onishi N, Newitt DC, Gibbs JE, Nguyen AA, Freimanis R, Price ER, Hwang S, Hylton NM. University of California, San Francisco, San Francisco, CA;Duke University School of Medicine, Durham, NC.
P3-03-19 Incidence and time to resolution of axillary adenopathy on mammography after COVID-19 vaccination
Robinson K, Maimone S, Advani PP, Li Z, Gococo-Benore D, Qosja N, Mummareddy A, Ahmed M Ashai, Wilhelm A, Maxwell R, Wasserman M, Patel N, Morozov A, Chumsri S. Mayo Clinic, Jacksonville, FL.
P3-03-20 The association of preoperative MRI with surgical decision-making in patients with early-stage breast cancer: A multi-institutional analysis
Borowsky PA, Choi S, Morgan O, White AK, Morin C, Net J, Kesmodel S, Goel N, Patel Y, Griffiths A, Feinberg JA, Kangas-Dick A, Andaz C, Giuliano C, Zelenko N, Manasseh D-M, Borgen P, Rojas KE. Division of Surgical Oncology, Dewitt Daughtry Department of Surgery, University of Miami, Miami, FL; Department of Surgery, Maimonides Medical Center, Brooklyn, NY; University Hospital of Quebec, Laval University, Quebec City, QC, Canada; Division of Breast Imaging, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; Wright Center for Graduate Medical Education, Scranton, PA; Department of Radiology, Maimonides Medical Center, Brooklyn, NY.
P3-03-21 Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: Whart do they mean?
Keymeulen K, Geurts S, Kooreman L, Duijm L, Engelen S, Vanwetswinkel S, Luiten E, Siesling S, Voogd A, Tjan-Heijnen V. Maastricht University Medical Centre, Maastricht, Netherlands; Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Amphia Hospital, Breda, Netherlands; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands; Department of Epidemiology, Maastricht University Medical Centre, Maastricht, Netherlands.
P3-03-22 Use of 64Cu-DOTA trastuzumab positron emission tomography to predict pathologic complete response in locally advanced HER2 positive breast cancer
Mortimer J, Rockne R, Liu J, Yuan Y, Stewart D, Waisman J, Frankel P, Kruper L, Adhikarla V. City of Hope, Duarte, CA.
P3-03-23 Surveillance breast magnetic resonance findings in asymptomatic CDH1 variant carriers
Gamble LA, Teke M, Fridling J, Samaranayake SG, Redd B, Blakely A, Davis JL. National Institutes of Health, Bethesda, MD.
P3-03-24 Machine learning approach to predict the level of tumor-infiltrating lymphocytes of breast cancer via MRI-based radiomics
Huang Y, Lin Y. the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
   
  Detection/Diagnosis - Imaging and Screening: Screening
P3-04-01 Information availability about screening for high-risk breast cancer on cancer center websites
Batra JS, Park E, Gupta A. University of South Alabama, Mobile, AL; University of Minnesota, Minneapolis, MN.
P3-04-02 Real world evidence demonstrates replacement of 2D mammography with 3D mammography among insured women
DaCosta Byfield S, Wimmer K, Adajar BA, Onglao P, Fredrickson A, Ventura ME, Staib J, Catlett K, Soonavala R, Kim M-O, Fiscalini A, Esserman L. OptumLabs at UHG, Minnetonka, MN; University of California, San Francisco, San Francisco, CA.
P3-04-03 The value of screening MRI in patients with high-risk breast lesions: An observational single-institution cohort study
Laws A, Katlin F, Hans M, Graichen M, Kantor O, Minami C, Bychkovsky B, Pace L, Scheib R, Garber J, King T. Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA.
P3-04-04 Multi-institutional perspective on screening mammography and breast cancer stage at diagnosis during the COVID-19 pandemic
Stephens SJ, Lloyd MR, Hong JC, Mehta T, James TA, Blitzblau R, Recht A, Spiegel DY. Duke University Medical Center, Durham, NC; Beth Israel Deaconess Medical Center, Boston, MA; University of California San Francisco, San Francisco, CA.
   
  Tumor Cell and Molecular Biology: Epigenetics
P3-05-01 Role of TRIM24 in metaplastic breast cancer and nomination of potential therapeutic targets
Shah V, Miao S, Yam C, Chang JT, Barton M, Piwnica-Worms H, Moulder S, Lozano G. UT MD Anderson Cancer Center, Houston, TX; University of Texas Health Sciences Center at Houston, Houston, TX; Cancer Early Detection Advanced Research Center, Portland, OR.
P3-05-02 A minimal DNA-methylation signature to estimate tumor content and molecular subtype in breast cancer tissue samples with potential application to liquid biopsy
Romagnoli D, Galardi F, De Luca F, Biagioni C, Moretti E, Biganzoli L, Migliaccio I, Malorni L, Benelli M. Azienda USL Toscana Centro, Prato, Italy.
P3-05-03 KMT2D as a novel therapeutic target for HER2+ breast cancers
Ma E, Zlobin A, Wyatt D, Ng J, Dingwall A, Osipo C. Loyola University Chicago, Maywood, IL; University of Chicago, Chicago, IL; Washington University in St. Louis, St. Louis, MO.
P3-05-04 The histone demethylase hairless functions as a tumor suppressor gene in breast cancer development
Liu L, Shen Y, Singh J, Sah B, Chen Z, Henzler C, Ha W, Su T, Hibshoosh H. University of Minnesota, Austin, MN; Columbia University Medical Center, New York, NY; University of Minnesota, Minneapolis, MN.
P3-05-05 Preclinical evaluation of novel HDAC6 selective inhibitors N008 with potent in vitroandin vivoprofiles in non-solid tumor and solid tumors
Shen X, Li Z. Convalife (Shanghai) Co.Ltd., Shanghai, China.
P3-05-06 Genome-wide DNA methylation analysis identifies novel biomarkers associated with risk of relapse beyond oncotype DX recurrence-score risk assessment within HR+/HER2- early-stage breast cancer patients
Fuentes-Antrás J, García-Barberán V, Costa-Fraga N, Moreno F, Bao-Caamano A, Rodríguez-Casanova A, López de Sá A, De Luna A, Lopez-Cade I, Ramirez-Ruda C, Pascual A, Perez-Segura P, Győrffy B, Ocaña A, Diaz-Lagares A, Garcia-Saenz JA. Servicio de Oncología Médica, Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain; Translational Medical Oncology Group (Oncomet), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain; Servicio de Anatomia Patológica, Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain4Semmelweis University, Budapest, Hungary.
P3-05-07 The response of histone deacetylase inhibitors in triple negative breast cancer
Alzoubi M, Nguyen K, Burks H, Hebert K, Cheng T, Matossian M, Wright M, Collins-Burow B, Burow M. Tulane University School of Medicine, New Orleans, LA; Northwestern University, Chicago, IL; University of Chicago, Chicago, IL.
   
  Tumor Cell and Molecular Biology: Epithelial-Mesenchymal Transition
P3-06-01 Eribulin alters the chromatin landscape to induce MET, attenuating metastatic progression and sensitizing breast tumors to subsequent chemotherapy
Pattabiraman DR, Bagheri M, Ognjenovic NB, LaCroix IS, Gerber SA. Geisel School of Medicine at Dartmouth, Lebanon, NH.
P3-06-02 Exosomes produced by adipocytes induce EMT, immune exhaustion and tumor metastasis, in both in vivo and in vitro models of TNBC
Qiu Y, Ross C, Jafari N, Kolla M, Llevenes P, Ennis C, Mazzeo CS, Mahdaviani K, Ko NY, Denis GV. Boston University, Boston, MA.
P3-06-03 NR2F1 is a barrier to dissemination of early-evolved mammary cancer cells
Rodriguez-Tirado C, Kale N, Carlini MJ, Shrivastava N, Rodrigues A, Khalil B, Bravo-Cordero JJ, Alexander M, Ji J, Soledad Sosa M. Icahn School of Medicine at Mount Sinai, New York, NY.
P3-06-04 Notch3 inhibits epithelia-mesenchymal transition by trans-activating GSK3β in breast cancer
Wei-Ling C, Zhang Y-Q, Huang W-H, Chen M, Li Y-C, Zhang G-J. Xiang’an Hospital of Xiamen University, Xiamen, China; Cancer Hospital of Shantou University Medical College, Shantou, China.
P3-06-05 Withdrawn
P3-06-06 Pg5 promotes breast cancer metastasis by activatingpi3k/akt/mtor signaling pathways
Xiang K, Yan W, Yanshan H, Xiaojia Y, Chunmei Z, Minmin G. The Second Affiliated Hospital of Kunming Medical University, Kunming, China; The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Hospital, Yunnan Cancer Center, Kunming, China.
P3-06-07 Glutathione peroxidase 8 (GPX8) as a novel therapeutic target in triple negative breast cancer
Khatib A. The Hebrew University, Jerusalem, Israel.
P3-06-08 JAM2 inhibits breast cancer invasion and migration by inhibiting the EMT process and potentially affects the immune microenvironment by increasing CXCL9/CXCL10
Peng Y. Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
   
  Tumor Cell and Molecular Biology: Genetics - Germline Changes
P3-07-01 Young women with breast cancer and high risk family history but no high penetrance germline mutations have a higher load of rare high functional impact germline variants in cancer relevant genes
Rozenblit M, Qing T, Ye Y, Zhao H, Hofstatter E, Singh V, Reisenbichler E, Murray M, Pusztai L. contributed equally to this work, Yale University, New Haven, CT; Yale University, New Haven, CT.
P3-07-02 Identification of potential germline variants (GV) on tumor comprehensive genomic profiling (CGP) in patients with advanced breast cancer (BC): BRCA1/2 and beyond
Tierno MB, Dougherty KC, Gornstein E, Pavlick DC, Schrock A, Oxnard GR. Foundation Medicine, Cambridge, MA.
P3-07-03 Real-world evidence database reveals 17.74% of individuals with breast cancer harbor a germline pathogenic or likely-pathogenic variant with implications for medical management and/or reproduction
Bontempo K, Wernecke C, Mauer C, Bentley B, Graham M, Whitworth P, Patel R, Beitsch P. Medneon, Cupertino, CA; Nashville Breast Center, Nashville, TN; Good Samaritan Hospital, Los Gatos, CA; Dallas Surgical, Dallas, TX.
P3-07-04 Geographical patterns of pathogenic genetic variants associated with hereditary breast, ovarian and prostate cancer (HBOPC) in Portugal
de Oliveira IC, Fragoso S, Santos S, Duarte T, Bexiga C, Mira B, Miguel I, Luís A, Vaz F. IPOLFG, Lisbon, Portugal.
P3-07-05 Genetic profile of germline mutations in unselected women with breast cancer in a Colombian population
Sierra-Díaz DC, Morel A, Fonseca DJ, Contreras N, Angulo-Aguado M, Balaguera V, Llinás-Caballero K, Munevar I, Borras M, Lema M, Idrobo H, Trujillo D, Serrano N, Orduz AI, Lopera D, Gonzalez J, Rojas G, Londoño P, Manneh R, Quintero C, Laissue P, Cabrera R, Restrepo CM, Mantilla W. Universidad del Rosario, Bogota, Colombia; Fundación Cardioinfantil-Instituto de Cardiología, Bogota, Colombia; Clínica de Oncología Astorga, Medellín, Colombia; Centro Médico Julián Coronel, Cali, Colombia; Hospital Internacional de Colombia, Bucaramanga-Piedecuesta, Colombia; Oncólogos del Occidente S.A.S, Armenia, Manizalez, Pereira, Colombia; Sociedad de Oncología y Hematología del Cesar - SOHEC, Valledupar, Colombia; Integrative IPS, Bogota, Colombia; BIOPAS Laboratoires, Orphan Disease Unit, Bogota, Colombia.
P3-07-06 Guideline-based multi-gene panel (MGP) testing for germline pathogenic variants among patients diagnosed with breast cancer: Regional perspectives
Abdel-Razeq H, Almasri R, Abujamous L, Al-Masri M, Hamed Allah M, Tamimi F, Edaily S, Abuhijla F, Salama O, Abdulelah H, Bater R. King Hussein Cancer Center, Amman, Jordan; Istishari Hospital, Amman, Jordan.
P3-07-07 Prevalence of BRCA 1/2 germinal mutation among young women with breast cancer: Experience in a third level private center
Vazquez-Juarez D, Serrano-Olvera JA, Noguez-Ramos A, Regalado-Porras GO, Lazaro-León JM, Olivares-Beltran G, Gerson-Cwilich R. Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico; ABC Medical Center, CDMX, Mexico.
P3-07-08 Germline mutational profiling in Indian TNBCs
Koppiker CB. Prashanti Cancer Care Mission, Pune, India.
P3-07-09 Single cell transcriptomic analysis reveals the effects of BRCA1 and BRCA2 mutations on distinct signaling networks and cancer susceptibility
Nakshatri H, Bhat-Nakshatri P, Chen D, Chen K, Mang H, Herodotou CA, Khatpe AS, McGuire PC, Xuei X, Liu Y, Sandusky G, Storniolo AM. Indiana University, Indianapolis, IN.
   
  Tumor Cell and Molecular Biology: Genetics - Somatic Changes
P3-08-01 Clonal hematopoiesis of indeterminate potential (CHIP) in metastatic triple negative breast cancer
Santos K, Jin Q, Miller PG, Patel A, Kirkner GJ, Files JL, Hughes ME, Stokes SM, Tayob N, Stover DG, Gibson CJ, Winer EP, Lin NU, Garber JE, Parsons HA. Dana-Farber Cancer Institute, Boston, MA; Ohio State University Comprehensive Cancer Center, Columbus, OH.
P3-08-02 The frequency and somatic mutation landscape of Fibroblast growth factor receptor (FGFR) alterations in breast cancer
Giridhar KV, Sokol ES, Vedell PT, Sinnwell JP, Desai A, Haddad TC, O’Sullivan CC, Leon-Ferre RA, Yadav S, Sideras K, Ernst B, Liu MC, Eyman Casey A, Tang X, Fleischmann Z, Murugesan K, Kalari KR, Goetz MP. Mayo Clinic, Rochester, MN; Foundation Medicine, Cambridge, MA; Mayo Clinic, Jacksonville, FL; Mayo Clinic, Scottsdale, AZ.
P3-08-03 HOXB13 is coamplified with HER2 in a subset of breast cancers
Sgroi D, Onozato M, Mitsiades I, McMullin R, Hicks D, Volorio A, Rheinbay E. Harvard Medical School, Boston, MA; AstraZeneca, Worcester, MA; Yale Medical School, New Haven, CT.
P3-08-04 The genomic and transcriptomic landscape of PIK3R1 mutated breast cancers
Cobleigh M, Okeke E, Mahon B, Mauer E, Barrett A, Abukhdeir A. Rush University Medical Center, Chicago, IL; Tempus, Chicago, IL.
P3-08-05 Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer
Kaplan HG, Berry AB, Dowdell A, Piening B. Swedish Cancer Institute, Seattle, WA; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR.
P3-08-06 Breast cancer patients categorized as high-risk of recurrence and/or basal-type molecular subtype by MammaPrint and BluePrint, respectively, should universally undergo germline genetic testing
Bentley BG, Wernecke C, Bontempo K, Graham M, Witworth P, Patel R, Beitsch P. Medneon, Cupertino, CA; Nashville Breast Cneter, Nashville, TN; Good Samaritan Hospital, Los Gatos, CA; Dallas Surgical, Dallas, TX.
P3-08-07 Comparison of the genomic alterations in metastatic inflammatory and non-inflammatory breast cancer
Richard F, De Schepper M, Maetens M, Leduc S, Isnaldi E, Geukens T, Van Baelen K, Nguyen H-L, Vermeulen P, Van Laere S, Dirix L, Floris G, Biganzoli E, Desmedt C. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium; Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, KU Leuven, Leuven, Belgium; Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) “L. Sacco” & DSRC, LITA Vialba Campus, Università degli Studi di Milano, Milan, Italy.
   
  Tumor Cell and Molecular Biology: Genomics
P3-09-01 A ubiquitination cascade regulating the integrated stress response and survival in carcinomas
Cervia LD, Shibue T, Gaeta B, Borah AA, Leung L, Li N, Dumont N, Gonzalez A, Bick N, Kazachkova M, Dempster JM, Krill-Burger JM, Piccioni F, Udeshi N, Olive ME, Carr SA, Root DE, McFarland JM, Vazquez F, Hahn WC. Dana-Farber Cancer Institute, Boston, MA; Broad Institute of MIT and Harvard, Cambridge, MA.
P3-09-02 Mutational assessment of newly diagnosed breast cancer using Germline and tumor genomICs
De Silva DL, Skandarajah AR, Sinclair M, Kentwell M, Devereux L, Zeethoven M, Hogg K, Lal L, Stafford L, James PA, Lindeman GJ, Mann GB, Campbell IG. Memorial Sloan Kettering, New York, NY; Peter MacCallum Cancer Centre, Melbourne, Australia; Centre for Women's Mental Health, Royal Women's Hospital, Melbourne, Australia; Parkville Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Australia; Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia; The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; Department of Surgery, The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia.
P3-09-03 Withdrawn
P3-09-04 Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations
Xi J, Harnden K, Luo J, Call GS, Mauer E, Ronski K, Ma CX, Vasan N. Washington University, St. Louis, MO; Inova Schar Cancer Institute, Fairfax, VA; Tempus Labs, Inc, Chicago, IL; Columbia University Irving Medical Center, New York, NY.
P3-09-05 Genomic and clinical characterization of breast tumors with unusual HER2 FISH pattern (ratio < 2, HER2 copy number ≥ 6): Are they mostly HER2 “positive?”
Wei CH, Yang L, Stewart D, Bedell V, Schmolze D, Apple S, Murata-Collins JL, Pillai R, Mortimer JE. City of Hope Comprehensive Cancer Center, Duarte, CA.
P3-09-06 Targeting tumor subpopulations based on single-cell transcriptomics
Grible JM, Leftwich T, Olex AL, Duong AK, Hairr N, Rashid NS, Smith TM, Signaevskaia L, Boyd DC, Dozmorov MG, Harrell JC. Virginia Commonwealth University, Richmond, VA.
P3-09-07 R-loop forming sequences determine early response genes and tumorigenic pathways driven in BRCA1-deficient carriers
Grageda A, Kuznetsov VA. SUNY Upstate Medical University, Syracuse, NY.
P3-09-08 An automated tool to determine optimal cluster numbers in single-cell RNA sequencing data identifies key prognostic subsets of T cells in breast tumors
Liu S, Thennavan A, Marron JS, Perou . University of North Carolina at Chapel Hill, Chapel Hill, NC.
P3-09-09 Serial circulating tumor DNA from patients with metastatic breast cancer with and without BRCA1/2 mutations
Collier KA, Tallman D, Weber ZT, Haynam M, Adams EJ, Jenison J, Asad S, Lustberg M, Cherian M, Ramaswamy B, Sardesai S, Williams N, Wesolowski R, Vandeusen J, Gatti-Mays ME, Pariser A, Mortazavi A, Stover DG. Ohio State University, Columbus, OH.
P3-09-10 NTRK1/2/3 fusions are observed in both secretory and non-secretory breast cancers
Sokol E, Maund S, Ross J, Wilson T. Foundation Medicine, Cambridge, MA; Genentech, South San Francisco, CA.
P3-09-11 Clinical characteristics associated withBRCA1/2mutations identified on routine tumor tissue genotyping in metastatic breast cancer
Vidula N, Blouch E, Farahani A, Marble H, Niemierko A, Hesler K, Denault E, Juric D, Ellisen LW, Moy B, Isakoff S, Lennerz J, Bardia A. Massachusetts General Hospital, Boston, MA.
P3-09-12 Breast cancer derived GATA3 mutations disrupt luminal transcriptional network
Takaku M, Saotome M, Nair R. University of North Dakota, Grand Forks, ND.
P3-09-13 Androgen receptor loss is associated with genomic instability characterized by copy number alterations and mirna deregulation in triple-negative breast cancer
Bhattarai S, Sugita BM, Cavalli L, Aneja R. Georgia State University, Atlanta, GA; Research Institute Pelé Pequeno Príncipe, Curitiba, Brazil.
P3-09-14 Whole exome sequencing of matched primary and metastatic triple-negative breast cancer samples
Kaur J, Chandrashekar DS, Varga Z, Janssen E, Gandhi K, Mittal K, Kiraz U, Varambally S, Aneja R. Georgia State University, Atlanta, GA; University of Alabama at Birmingham, Birmingham, AL; University Hospital Zurich, Department of Pathology and Molecular Pathology, Zurich, Switzerland; Stavanger University Hospital, Department of Pathology, Stavanger, Norway; Winship Cancer Institute, Emory University, Atlanta, GA;; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.
P3-09-15 Value-added clinical tumor/normal whole exome and whole transcriptome sequencing versus a DNA and RNA tumor only gene panel for managing breast cancer
Cole KS, Li Z, Tiersten A, Zhang W, Al-Kateb H, Hantash FM, Rossi MR, Newman S, Zhou X, Schadt EE, Chen R, Oh WK, Fink MY. Sema4 Genomics, Stamford, CT; Sema4Genomics, Stamford, CT; Mount Sinai School of Medicine, New York, NY.
P3-09-16 Validating alternative splicing events between bulk and scRNA sequencing data: A bioinformatic approach
Cottone G, Spike BT, Mirzaei Mehrabad E, Seema A Khan SA, Clare S. Department of Surgery, Lurie Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL; Huntsman Cancer Institute, Department of Oncological Sciences, University of Utah, Salt Lake City, UT; School of Computing, University of Utah, Salt Lake City, UT.
P3-09-17 Systems-scale characterization of the human immunome in breast cancer for precision medicine
Yi S. University of Texas at Austin, Austin, TX.
P3-09-18 The association between genomic alterations and body mass index in patients with early breast cancer
Nguyen H-L, Geukens T, Maetens M, Van Baelen K, De Schepper M, Leduc S, Isnaldi E, Aparicio S, Borg A, Brock J, Broeks A, Caldas C, Green A, Khout H, Jórunn E, Knappskog S, Krishnamurthy S, Lakhani S, Langerod A, Martens JWM, Murphy L, Nik-Zaina S, Purdie C, Rakha E, Richardson A, Salomon A, Simpson P, Sotiriou C, Span P, Tan BK, Thompson A, Tommasi S, Van de Vijver M, Van Laere S, Viari A, Floris G, Biganzoli E, Richard F, Desmedt C. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Leuven, Belgium; BC Cancer Research Institute, Vancouver, BC, Canada; Lund University, Lund, Sweden; Department of Pathology, Brigham & Women’s Hospital, Boston, MA; The Netherlands Cancer Institute, Amsterdam, Netherlands; University of Cambridge, Cambridge, United Kingdom; Nottingham Breast Cancer Research Centre, University of Nottingham, Nottingham, United Kingdom; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; University of Iceland, Reykjavik, Iceland; Department of Clinical Science, University of Bergen and Department of Oncology, Haukeland University Hospital, Bergen, Norway; MD Anderson Cancer Center, Houston, TX; University of Queensland/Pathology Queensland, Brisbane, Australia; Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Erasmus University Medical Center, Rotterdam, Netherlands; University of Manitoba and CancerCare Manitoba, Winnipeg, MB, Canada; University of Dundee, Dundee, United Kingdom; Johns Hopkins Medicine, Washington DC, DC; Diagnostic and Theranostic Medicine Division, Institut Curie, PSL Research University, Paris, France; University of Queensland, Brisbane, Australia; Institut Jules Bordet, Brussels, Belgium; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, Netherlands; Department of General Surgery, Sengkang General Hospital, Singapore, Singapore; Istituto tumori Giovanni Paolo II, Bari, Italy; Amsterdam University Medical Centre, Amsterdam, Netherlands; Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium; INRIA, Grenoble, France; Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Unit of Medical Statistics, Biometry and Epidemiology, Department of Biomedical and Clinical Sciences (DIBIC) “L. Sacco” & DSRC, LITA Vialba campus, Università degli Studi di Milano, Milan, Italy.
P3-09-19 The utility of using genomic testing on needle core biopsies during the COVID-19 pandemic: Molecular characterization, risk stratification, neoadjuvant outcome, and future implications
Katerji H, Zhang H, Wang X, Schiffhauer L, Dhakal A, Huston A, Falkson C, Hicks D, Turner B. University of Rochester, Rochester, NY.
   
  Tumor Cell and Molecular Biology: MicroRNAs and Other Non-coding RNAs
P3-10-01 Mir-150 expression is associated with immune cell infiltration and immune response in breast cancer
Oshi M, Gandhi S, Wu R, Yan L, Yamada A, Ishikawa T, Endo I, Takabe K. Roswell Park Comprehensive Cancer Center, Buffalo, NY; Yokohama City University Graduate School of Medicine, Yokohama, Japan; Tokyo Medical University, Tokyo, Japan.
P3-10-02 Enhanced miR-579-3p by anti-estrogen treatment may affect capecitabine response in hormone receptor positive metastatic breast cancer
Lee J, Joe SY, Lee J-S, Kim D-M, Seoul LA. St. Mary's Hospital, Seoul, Republic of Korea.
P3-10-03 Enrichment of pro-oncogenic immune miRNAs in exosomes by cyclin D1, promote cancer stem cell expansion
Jiao X, Xu C, Tian L, Zhang Z, Ashton AW, Li Z, Pestell RG. Baruch S Blumberg Institute, Doylestown, PA; Thomas Jefferson University, Philadelphia, PA; Lankenau Institute for Medical Research, Wynnewood, PA.
P3-10-04 microRNA-125a high expressing tumors enrich cell proliferation associated gene sets and associated with poor prognosis in estrogen receptor positive breast cancer patients
Tokumaru Y, Futamura M, Taniguchi K, Oshi M, Mase J, Asano Y, Mori R, Takabe K, Yoshida K. Gifu University School of Medicine, Gifu City, Japan; Osaka Medical and Pharmaceutical University, Takatsuki, Japan; Roswell Park Comprehensive Cancer Center, Buffalo, NY.
P3-10-05 Feasibility of detecting long noncoding RNAs in clinical FFPE specimens using clinical grade RNA-sequencing pipeline
Wei CH, O'Meally D, Kirschenbaum M, Mao A, Kancharla C, Morris KV, Stewart D. City of Hope Comprehensive Cancer Center, Duarte, CA.
P3-10-06 High levels of miR-18a is associated with increased proliferation but suppression of EMT phenotype in ER negative breast cancer
Nair MG, Chandrakala M, Apoorva D, Snijesh VP, Prabhu JS, Rajarajan S, Korlimarla A, Ramesh RS, Srinath BS, Sridhar TS. St. John's Research Institute, Bangalore, India; Shankara Cancer Hospital and Research Centre, Bangalore, India; St. John's Medical College and Hospital, Bangalore, India; Indian Institute of Science Education and Research, Berampur, India.
   
  Tumor Cell and Molecular Biology: Virology
P3-11-01 Withdrawn
P3-11-02 Evaluation of the effects of anticancer treatments in cancer patients undergoing SARS-COV2 vaccination (VAX-on study: Breast cancer subgroup analysis)
Fabbri A, Marrucci E, Nelli F, Mazzotta M, Onorato A, Francesca P, Chilelli MG, Virtuoso A, Signorelli C, Giron Berrios JR, Schirripa M, Donghia R, Ruggeri EM. Belcolle Hospital, Viterbo, Italy; Belcolle Hospital, viterbo, Italy; National Institute of Gastroenterology "Saverio de Bellis", Castellana Grotte, Italy.
   
  Epidemiology, Risk, and Prevention: Epidemiology - Population Studies
P3-12-01 Regular aspirin use, breast tumor characteristics and long-term breast cancer survival
Peng C, Holmes MD, Wang T, Harris A, Chen W, Brantley K, Heng YJ, Bret-Mounet VC, Baker GM, Rosner B, Willett W, Tamimi R, Eliassen AH. Brigham and Women's Hospital, Boston, MA; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Institute, Boston, MA; ‪Beth Israel Deaconess Medical Center, Boston, MA; Harvard T. H Chan School of Public Health, Boston, MA; Weill Cornell Medicine, NY, NY.
P3-12-02 Loss of PTEN expression, PIK3CA mutations, and breast cancer survival in the Nurses’ health studies
Wang T, Heng YJ, Baker GM, Bret-Mounet VC, Hankinson SE, Holmes MD, Chen WY, Willett WC, Rosner BA, Tamimi RM, Eliassen AH. Brigham and Women's Hospital and Harvard Medical School, and Harvard T. H. Chan School of Public Health, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; University of Massachusetts Amherst School of Public Health and Health Sciences, Amherst, MA; Dana-Farber Cancer Institute, and Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Weill Cornell Medicine and Harvard T. H. Chan School of Public Health, Boston, MA.
P3-12-03 Pre-diagnostic plasma 25-hydroxyvitamin D and mortality among women with breast cancer in the nurses’ health study cohorts
Holder E. UMASS Amherst, Amherst, MA.
P3-12-04 Extending therapy after 5-year adjuvant hormone therapy in breast cancer patients: A population-based study
Zeng E, He W, Bergqvist J, Czence K. Karolinska Institutet, Stockholm, Sweden.
P3-12-05 Influence of environmental temperature on breast cancer outcomes: A SEER population-based study
Gupta A, Attwood K, Gupta K, Catalfamo K, Takabe K, Gandhi S. Roswell Park Comprehensive Cancer Center, Buffalo, NY; University of Massachusetts Medical School - Baystate, Springfield, MA.
P3-12-06 Prognosis of pregnancy-associated breast cancer: Inferior outcome in patients diagnosed during second and third gestational trimesters and lactation
Suelmann BBM, Bakhuis CFJ, van Dooijeweert C, Verloop J, Zweemer RP, Linn SC, van der Wall E, van Diest PJ. UMC Utrecht, Utrecht, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands
P3-12-07 Breast cancers are overrepresented in school teachers, particularly of young students
Gagnon J, Wernick MH. Washington and Lee University, Lexington, VA; Frederick Health Hospital, Frederick, MD.
P3-12-08 Neighborhood disadvantage predicts worse breast cancer-specific survival
Goel N, Choi S, Yadegarynia S, Rojas K, Kesmodel S, Kobetz E, Westrick A. University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL; University of Michigan, Department of Public Health, Ann Arbor, MI.
P3-12-09 Impact of the COVID-19 outbreak on the treatment strategy of Dutch breast cancer patients
Eijkelboom AH, Siesling S, de Munck L, van den Bongard DHJG, Menke-van der Houven van Oordt W, Westenend PJ, Siemerink EJM, Strobbe LJA, Vrancken Peeters M-JTFD, Koppert LB, Mureau MAM, Jager A, Broeders MJM, Lobbes MBI, Verkooijen HM, Wesseling J, Smidt M, Tjan-Heijnen VCG, NABON-COVID-19 consortium, COVID and Cancer Care NL consortium (ZONMW number10430022010014). Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands; Amsterdam UMC, Amsterdam, Netherlands; Amsterdam UMC - location VUmc, Amsterdam, Netherlands; Laboratory of Pathology, Dordrecht, Netherlands; Hospital Group Twente (ZGT), Hengelo/Almelo, Netherlands; Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, Netherlands; Erasmus University Medical Center, Rotterdam, Netherlands; Erasmus MC Cancer Institute, Rotterdam, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; Zuyderland Medical Center, Sittard-Geleen, Netherlands; University Medical Centre Utrecht, Utrecht, Netherlands; Maastricht University Medical Centre, Maastricht, Netherlands; Maastricht University Medical Centre (School of GROW), Maastricht, Netherlands .
P3-12-10 Socioeconomic status in young breast cancer patients is associated with inequalities in recurrence patterns: A population-based study in the Netherlands
van Maaren MC. Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
P3-12-11 Survival differences in Filipino versus white women with breast cancer in the United States: A SEER-based analysis
Lim DW, Giannakeas V, Narod SA. Women’s College Hospital, Toronto, ON, Canada.
P3-12-12 ATTITUDE: Understanding and reducing ATTrition in longiTUDinal studiEs of cancer survivors
Lapidari P, Havas J, Presti D, Soldato D, Martin E, Pistilli B, Bertaut A, Boinon D, Jacob G, Martin A-L, Everhard S, Jacquet A, Menvielle G, Lambertini M, Vanlemmens L, Michiels S, André F, Vaz-Luis I, Di Meglio A. Institut Gustave Roussy, Villejuif, France; Centre George-Francois Leclerc, Dijon, France; Seintinelles, Paris, France; UNICANCER, Paris, France; Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; Università degli Studi di Genova, Genova, Italy; Centre Oscar Lambret, Lille, France.
P3-12-13 Evaluation of disparities in anxiety, depression, and cancer empowerment in a study of BRCA1/2-positive females in the United States
Dibble KE, Connor AE. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
P3-12-14 Attenuated negative prognostic effect of progesterone receptor negativity in postmenopausal ER+ breast cancer with normal BMI (<25): A nation-wide study in Korean Breast Cancer Society and the institutional cohort
Bae SJ, Hwang J, Lee J, Ji JH, Chu C, Kim JH, Ahn SG, and Joon Jeong J. Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
P3-12-15 Clinical characteristics, treatment patterns, and survival outcomes in women with early triple-negative (TN) or hormone receptor-positive/human epidermal growth factor receptor-2 negative (HR+/HER2) breast cancer (BC) in the real-world (RW) setting
Gogate A, Crosbie A, Le TK, Zhang Y, Das R, Davis C. Bristol Myers Squibb, Princeton, NJ
P3-12-17 Breast cancer treatment related survival gains in the African breast cancer - Disparities in outcomes study
Foerster M, Kantelhardt E, Boucheron P, dos-Santos-Silva I, McCormack V, the ABC-DO study team. International Agency for Research on Cancer, 69372 LYON cedex 08, France; University of Halle-Wittenberg, 06108 Halle, Germany; London School of Hygiene and Tropical Medicine, London, United Kingdom.
P3-12-18 Withdrawn
P3-12-19 Associations of alcohol consumption with benign breast tissue composition
Yaghjyan L, Austin-Datta R, Heng YJ, Baker G, Rosner B, Tamimi R. University of Florida, Gainesville, FL; Department of Pathology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
P3-12-20 Outcomes of patients with pathologic complete response following neoadjuvant HER2-targeted therapy in patients with HER2+ early stage breast cancer
O'ShaughnessyJ, Oestreicher N, Fulcher N, Tseng W-Y, Beeks A, Moore J, Lalla D. Baylor Univesity Medical Center, Texas Oncology, Dallas, TX; Puma Biotechnology, Inc., Los Angeles, CA; Ontada, The Woodlands, TX.
P3-12-21 Blood pressure and the subsequent risk of breast cancer: Findings from the Health Examinees-Gem Study
De la Torre K, Shin W-K, Huang D, Lee H-W, Shin A, Lee J-k, Lee H-Y, Kang D. Seoul National University, Seoul, Republic of Korea.
P3-12-22 Socioeconomic position and prognosis in premenopausal breast cancer: A population-based cohort study in Denmark
Hjorth C, Damkier P, Ejlertsen B, Lash TL, Sørensen HT, Cronin-Fenton D. Aarhus University Hospital, Aarhus N, Denmark; Southern University of Denmark, Odense, Denmark; Rigshospitalet, Copenhagen, Denmark; Emory University, Atlanta, GA.
P3-12-23 Characterization of triple-negative breast cancer in two Central American countries
Reyes-Morales A, Alvarado-Muñoz JF, Bejarano S, Castro H, Puac-Polanco V, Chivalan M, Torselli S. Roosevelt Hospital, Guatemala, Guatemala; Hospital de la Liga contra el Cáncer, Honduras, Honduras; Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala; Department of Health Care Policy, Harvard Medical School, Boston, MA.
P3-12-24 Landscape of germline BRCA1 and BRCA2 mutations in breast cancer in Peru
Pinto JA, Ferreyra Y, Cock-Rada AM, Doimi F, Casas J, Araujo J, Rosas G, Bravo L, Belmar-López C. Centro de Investigacion Básica y Traslacional, AUNA Ideas, Lima, Peru; Bioingenieria, UTEC, Lima, Peru; Instituto de Cancerologia Las Americas, AUNA, Medellin, Colombia; ONCOGENOMICS, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, INEN, Lima, Peru; Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Peru.
P3-12-25 Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study
Kim H, Kim SS, Lee JS, Yoon JS, Shin HJ, Lee JE, Lee SK, Chung IY, Jung S-Y, Choi YJ, Korean Breast Cancer Society. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Korea University, Department of Biostatistics, Seoul, Republic of Korea; Department of Surgery, Myongji Hospital, Seonam University College of Medicine, Goyang, Republic of Korea; Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea; Department of Surgery, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
P3-12-26 Baseline characteristics and survival of neuroendocrine carcinoma of the breast- A SEER database analysis
Alvarez Soto A, Anampa J. NYCHHC/Jacobi, New York, NY; Montefiore Medical Center, New York, NY.
P3-12-27 Characteristics and survival outcomes of male breast cancer in Sao Paulo state of Brazil: A population-based study
Frederice RdO, Pereira AAL, de Andrade FEM, Hanna SA, Carvalho HdA, Marta GN. Sirio Libanes Hospital, São Paulo, Brazil.
P3-12-28 Reproductive factors and molecular subtypes of breast cancer in premenopausal and postmenopausal women from 3 Colombian cities: PRECAMA & POSCAMA studies
Zambrano JA, Idarraga MDM, Agudelo S, Arias S, Zambrano Y, Cardenas K, Jurado D, Agudelo MC, Vasco E, Mondul A, Rozek L, Ossa A, Borrero M, Herazo F, Navarro E, Jaramillo R, Romieu I, Rinaldi S, Sánchez GI. Grupo Infección y Cáncer, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia; Department of Environmental Health Sciences and Risk Science Center, University of Michigan, Ann Arbor, MI; Hospital General de Medellín, Medellín, Colombia; Departamento de Ginecología y Obstetricia, Universidad de Antioquia, Medellín, Colombia; Clínica Vida Fundación, Medellín, Colombia; Universidad del Norte, Barranquilla, Colombia; Hemato Oncólogos S.A., Cali, Colombia; International Agency for Research on Cancer, Lyon, France.
P3-12-29 Effect of the COVID outbreak on detection of second primary breast cancer and breast cancer recurrences
Eijkelboom AH, de Munck L, Wesseling J, Westenend PJ, van den Bongard DHJG, Hendriks MPWA, Broeders MJM, Strobbe LJA, Bessems M, Honkoop AH, Lobbes MBI, Tjan-Heijnen VCG, Siesling S, and NABON-COVID-19 consortium and the COVID and Cancer Care-NL consortium. Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands; Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, Netherlands; Laboratory of Pathology, Dordrecht, Netherlands; Amsterdam UMC - Location VUMC, Amsterdam, Netherlands; Bernhoven Hospital, Uden, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands; Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Jeroen Bosch Hospital, Den Bosch, Netherlands; Isala Clinics, Zwolle, Netherlands; Zuyderland Medical Center, Sittard-Geleen, Netherlands; Maastricht University Medical Centre (School of GROW), Maastricht, Netherlands.
P3-12-30 Impact of medicaid expansion on breast cancer stage at diagnosis: Exploring the mechanisms at play
Koroukian SM, Dong W, Albert J, Kim U, Rose J, Owusu C, Zanotti K, Cooper G, Tsui J.Case Western Reserve University, Cleveland, OH;University of Southern California, Los Angeles, CA
P3-12-31 A 10 year retrospective study of male breast cancer patients within central Scotland
Morris REL, Pitsinis V. University Of Dundee, Dundee, United Kingdom; University Of Dundee & NHS Tayside Breast Unit, Dundee, United Kingdom.
P3-12-32 Long-term outcomes among young Saudi women with breast cancer
Aboualkhair OA, Omair A, Masuadi E, Alamri G, Aljehani A, Alkushi A, Partridge A. Dr. Sulaiman Al Habib Medical Group, Riyadh, Saudi Arabia; King Saud Bin Abdulaziz University for Health Sciences & King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Imam University, Riyadh, Saudi Arabia; King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center & King Abdulaziz Medical City - Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia; Dana-Farber Cancer Institute, Boston, MA.
P3-12-33 Breast cancer incidence rates in Japan showed unimodal age distribution
Uchida K, Ohashi H, Nogi H. Meiji Yasuda Shinjuku Kenshin Center, Shinjuku-Ku, Japan; The Jikei University of Medicine, Minato-Ku, Japan.
P3-12-34 Antibiotic use and mortality from triple-negative breast cancer
Ransohoff JD, Andrade K, Purington N, Balasubramanian V, Han S, Liu M, Caswell-Jin J, Sledge G, Bhatt A, Kurian A. Stanford University, Palo Alto, CA.
P3-12-35 Industrial and ruminant trans fatty acid intakes and cancer risk: Results from the NutriNet-Santé cohort
Wendeu-Foyet G, Chajes V, Huybrechts I, Bard J-M, Debras C, Chazelas E, Srour B, Zelek L, Julia C, EKesse-Guyot E, Agaësse C, Druesne-Pecollo N, Galan P, Hercberg S, Deschasaux-Tanguy M, Touvier M. Sorbonne Paris Nord University- INSERM U1153- INRAe U1125- CNAM- Nutritional Epidemiology Research Team (EREN)- Epidemiology and Statistics Research Center – University of Paris (CRESS), Bobigny, France; Nutrition and Metabolism Branch- International Agency for Research on Cancer, Lyon, France; Laboratoire de Biochimie Générale et Appliquée- UFR de Pharmacie- MMS-EA 2160-Mer Molécules Santé- IUML-Institut Universitaire Mer et Littoral-FR3473 CNRS, Nantes, France.
P3-12-36 The diagnosis and prognosis of ductal carcinoma in situ (DCIS) with microinvasion - Results from the United Kingdom Sloane project
Shaaban AM, Hilton B, Clements K, Dodwell D, Sharma N, Kirwan C, Sawyer E, Maxwell A, Wallis M, Stobart H, Mylvaganam S, Litherland J, Brace-Mcdonnell S, Dulson-Cox J, Kearins O, Provenzano E, Pinder S, Thompson A. Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom; Public Health England Screening, Birmingham, United Kingdom; University of Oxford, Oxford, United Kingdom; Leeds Teaching Hospital NHS Trust, Leeds, United Kingdom; University of Manchester, Manchester, United Kingdom; King’s College London and Guy’s and St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom; Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; Independent Cancer Patient Voice, London, United Kingdom; Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom; NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; University of Warwick, Warwick, United Kingdom; King's College London and Guy’s and St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom; Baylor College of Medicine, Houston, TX.
P3-12-37 The impact of the COVID-19 outbreak on breast cancer stage in the Netherlands by screening status
Eijkelboom AH, Siesling S, de Munck L, van Gils CH, Lobbes MBI, Tjan-Heijnen VCG, Strobbe LJA, Wesseling J, Pijnappel RM, Broeders MJM, NABON-COVID-19 consortium, COVID and Cancer Care-NL consortium (ZONMW number10430022010014). Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands; Julius Center for Health Sciences and Primary Care - University Medical Center, Utrecht, Netherlands; Zuyderland Medical Center, Sittard-Geleen, Netherlands; Maastricht University Medical Centre (School of GROW), Maastricht, Netherlands; Canisius Wilhelmina Hospital, Nijmegen, Netherlands; Netherlands Cancer Institute – Antoni van Leeuwenhoek, Amsterdam, Netherlands; University Medical Centre Utrecht, Utrecht, Netherlands; Radboud University Medical Center, Nijmegen, Netherlands.
   
  Epidemiology, Risk, and Prevention: Epidemiology - Genetic and Molecular
P3-13-01 Association of polygenic risk score with 2 year risk of poor prognosis breast cancer
McCarthy AM, Manning AK, Hsu S, Moy B, Lehman CD, Armstrong K. University of Pennsylvania School of Medicine, Philadelphia, PA; Massachusetts General Hospital, Boston, MA.
P3-13-02 A genome-wide association study of mammographic texture variation
Liu Y, Jiang X, Turman C, Vachon CM, Tamimi R, Kraft P. Harvard T.H. Chan School of Public Health, Boston, MA; Karolinska Insitutet, Stockholm, Sweden; Mayo Clinic, Rochester, MN; Weill Cornell Medical College, New York, NY.
P3-13-03 Heterozygous BRCA1 mutation influences alternative splicing in human benign mammary organoids
Lee O, Choi M-R, Cottone G, Patel P, Clare SE, Khan SA. Northwestern University, Chicago, IL.
P3-13-04 Clinical features and genetic alterations in patients (pts) with HER2-positive breast cancer (BC) and central nervous system (CNS) metastases (mets) in the real world
Dhillon PK, Lambert P, Sanglier T, Knott A, Restuccia E, de Haas SL, Lambertini C. Genentech, Inc., South San Francisco, CA; F. Hoffmann-La Roche Ltd., Basel, Switzerland.
P3-13-05 Comprehensive analysis of global genetic ancestry and socioeconomic status on breast cancer outcomes
Rodriguez DA, Yadegarynia S, Harbour JW, Merchant NB, Kobetz EN, Goel N. Sylvester Comprehensive Cancer Center; University of Miami, Miami, FL; University of Miami, Miami, FL.
P3-13-06 Single nucleotide polymorphisms and mortality after docetaxel-based chemotherapy in premenopausal breast cancer: A population-based cohort study in Denmark
Hjorth CF, Damkier P, Stage TB, Feddersen S, Ejlertsen B, Lash TL, Hamilton-Dutoit S, Ahern TP, Rørth M, Sørensen HT, Cronin-Fenton D. Aarhus University Hospital, Aarhus N, Denmark; University of Southern Denmark, Odense, Denmark; Odense University Hospital, Odense, Denmark; Rigshospitalet, Copenhagen, Denmark; Emory University, Atlanta, GA; University of Vermont, Burlington, VT.
P3-13-07 A comprehensive germline genetic landscape in young Jewish & Arab women with breast cancer
Rennert G, Nehoray B, Lejbkowicz F, Dishon S, Kalet S, Herzog J, Slavin T, Castillo D, Tsang K, Sand S, Rennert HS, Weitzel J. Carmel Medical Center and Technion Faculty of Medicine, Haifa, Israel; Division of Clinical Cancer Genomics, City of Hope, Duarte, CA; Division of Clinical Cancer Genomics, City of Hope, Duate, CA; Latin American School of Oncology, Sierra Madre, CA.
P3-13-08 Fusion analysis including NTRK fusion in breast cancers (BC): From RNASeq data analysis from 629 BC tissue samples
Kim J-Y, Park K, Park W-Y, Lee JE, Kim SW, Nam SJ, Yu J, Im Y-H, Ahn JS, Park YH. Samsung Medical Center, Seoul, Republic of Korea; Samsung Genome Institute, Seoul, Republic of Korea.
   
  Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects
P3-14-01 Withdrawn
P3-14-02 Racial/ethnic differences in the benefit of adjuvant chemotherapy for breast cancer patients with an intermediate risk 21-gene recurrence score
Ching Huang H-C, Calip GS, Weiss J, Simons Y, Gadi VK, Danciu OC, Rauscher GH, Hoskins KF. University of Illinois College of Pharmacy, Chicago, IL; University of Illinois at Chicago, Division of Hematology/Oncology, Chicago, IL; University of Illinois School of Public Health, Chicago, IL.
P3-14-03 The DNA damage repair landscape in Black women with breast cancer
Mazumder A, Jimenez A, Ellsworth RE, George S, Freedland SJ, Bainbridge MN, Haricharan S. Sanford Burnham Prebys, La Jolla, CA; Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD; Sylvester Comprehensive Cancer Center, Miami, FL; Cedars Sinai Medical Center, Los Angeles, CA; Rady Children's Hospital Institute for Genomic Medicine, San Diego, CA.
P3-14-04 Genetic testing in non-Hispanic Black women with breast cancer treated within an equal-access healthcare system
Ellsworth R, Vargason A, Turner C, Shriver C. Murtha Cancer Center, Windber, PA; Walter Reed National Military Medical Center, Bethesda, MD; Uniformed Services University of the Health Sciences, Bethesda, MD.
P3-14-05 Racial/ethnic disparities in cancer mortality after a second breast cancer
Deng Z, Jones MR, Wang M-C, Visvanathan K. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Johns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, Baltimore, MD.
P3-14-06 A transdisciplinary approach for characterizing racial differences in the biology of breast cancer by integrating imaging and -omics data
Liadis N, Earnest T, Bruan E, Antony A, Hallock M, Cook D. SimBioSys, Inc., Champaign, IL; Michiana Hematology Oncology, Westville, NE; Rush University Medical Center, Chicago, IL.
P3-14-07 Breast cancer screening disparities among insured women in the Washington DC-Baltimore area
Staib J, Catlett K, Dacosta Byfield S. OptumLabs, Minnetonka, MN
P3-14-08 The influence of metabolic factors, migration, and ethnic disparities on breast cancer risk and treatment
Lofterød T, Frydenberg H, Veierød M, Jenum AK, Reitan JB, Wist E, Thune I. Oslo University Hospital, Oslo, Norway; University of Oslo, Oslo, Norway.
P3-14-09 Breast cancer disparities through an imaging lens: Are black women more likely to have cancer detected on their first mammogram?
Wilkerson A, Obi M, Ortega Estrella C, Tu C, Pederson H, Al-Hilli Z. Cleveland Clinic, Cleveland, OH.
P3-14-10 Breast cancer patterns, behavior and survival among American Indians in the west north central region and the other regions of the U.S.
Gaba AG, Cao L, Renfrew R, Witte D, Wernisch J, Lutkemeier D, Egland K, Crosby R. Sanford Roger Maris Cancer Center, Fargo, ND; Sanford Research, Fargo, ND; Sanford Cancer Registry, Fargo, ND; Sanford Research, Sioux Falls, SD; Sanford Cancer Registry, Sioux Falls, SD; SAB Biotherapeutics, Sioux Falls, SD.
P3-14-11 Mammaprint and Blueprint identify genomic differences in HR+ HER2- breast cancers from young Black and White women
Reid S, Pal T, Mayer IA, Shu X-O, Tezak AL, Hoskins K, Sharma D, Robinson P, Wei J, Ruby J, Wang S, Haan J, Menicucci A, Audeh W, FLEX Investigators Group. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, IL; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; Stritch School of Medicine, Loyola University Chicago, Maywood, IL; Agendia Inc., Irvine, CA; Agendia NV, Amsterdam, Netherlands.
P3-14-12 Distinct and targetable molecular features of breast cancer in African American women
Magliocco G, Khalife R, Magliocco A. Boston University School of Medicine, Boston, MA; University of South Florida, Tampa, FL; Protean BioDiagnostics Inc, Orlando, FL.
P3-14-13 Metabolic links to socioeconomic stresses uniquely affecting race in normal breast tissue at risk for breast cancer
Angel PM, Park Y, Scott DA, Rujchanarong D, Brown S, Drake RR, Sandusky GE, Nakshatri H. Medical University of South Carolina, Charleston, SC; University of Wisconsin-Madison, Madison, WI; Indiana University School of Medicine, Indianapolis, IN.
P3-14-14 A mediation analysis of racial disparity in breast cancer survival
Hines RB, Zhu X, Lee E, Rapp C, Volk A, Johnson AM. University of Central Florida, Orlando, FL;Stetson University, DeLand, FL.
P3-14-15 The impact of race and age on response to neoadjuvant therapy and long-term outcomes in black and white women with early-stage breast cancer
Terman E, Sheade J, Zhao F, Howard FM, Jaskowiak N, Tseng J, Hahn O, Fleming G, Olopade OI, Huo D, Nanda R. UChicago Medicine, Chicago, IL.
P3-14-16 Prevalence of low estrogen receptor and low progesterone receptor positivity at an urban safety net hospital
Angell C, Bullock J, Diaz A, Basha R, Narra K. University of North Texas Health Science Center Texas College of Osteopathic Medicine, Fort Worth, TX; Oncology and Infusion Center, JPS Health Network, Fort Worth, TX.
P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis
Wallenta Law J, BuAli H, Costa S, Mullane MP, Hendawi M, McPhee M, Collini R, Teka M, Coutinho F, Broome R, Wolf FM, Toland L, Weber1 T, Berry A, Brown TD, Ali H. Syapse, San Francisco, CA; Ascension, Milwaukee, WI; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI; AdventHealth, Altamonte Springs, FL; Henry Ford Health System, Detroit, MI.
P3-14-18 Adaptive stress response genes associated with breast cancer subtypes and survival outcomes reveal race-related differences
Al Abo M, Gearhart-Serna L, Van Laere S, Freedman J, Patierno S, Hwang E-S, Krishnamurthy S, Williams K, Devi G. Duke University, Durham, NC; University of Antwerp, Antwerp, Belgium; MD Anderson Cancer Center, Houston, TX; North Carolina Central University, Durham, NC.
   
  Epidemiology, Advocacy, and Education: Ethnic/Racial Aspects
p3-14-19 Racial and ethnic groups have different clustering of common cancer genes
Beitsch P, Wernecke C, Bontempo K, Bentley B, Graham M, Whitworth P, Patel R. Dallas Surgical, Dallas, TX; Medneon, Cupertino, CA; Nashville Breast Center, Nashville, TN; Good Samaritan Hospital, Los Gatos, CA.
   
  Psychosocial, QOL, and Educational Aspects- Social and Education Issues: Advocacy
P3-15-01 Patients and Researchers Together (PART); a patient-centered tumor tissue collection PARTnership between patients and researchers to increase tissue donations for breast cancer research
Spears PA, Branch V, Potter JA, Van Lokeren M, Babadi NH, Beltran AS, Betts L, Crespo C, Dean B, Garrett AL, Jensen LT, Johnson GL, Morris H, Spanheimer P, Perou CM, Carey LA, Earp HS. University of North Carolina, Lineberger Comprehensive Cancer Center, Patient Advocates for Research Council, UNC Breast SPORE Advocacy, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, UNC Breast SPORE Advocacy, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Community Outreach and Engagement, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Office of Lineberger Sponsored Clinical Research, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Department of Genetics, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Patient Advocates for Research Council, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Office of Clinical and Translational Research, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Department of Pharmacology, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Department of Surgery, Chapel HIll, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
P3-15-02 Assessing the engagement related needs of researchers and patient advocates at the UNC Lineberger Comprehensive Cancer Center
Blount T, Gora Combs K, Mann Norwood C, Skywark ER, Potter JA, Zhang A, Spears PA. University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, NC; University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
P3-15-03 Imaging and invasive lobular carcinoma: A survey study conducted by the lobular breast cancer alliance
Hutcheson LB, Axelrod J, Fitzwater CL, Jochelson MS, Joergensen GH, Langdon T, Levine JK, Metzger O, Mitchell-Daniels M, Neilsen BF. Lobular Breast Cancer Alliance, Calabasas, CA; Memorial Sloan Kettering Cancer Center, New York, NY; Dana-Farber Cancer Institute, Boston, MA.
P3-15-04 How can we help: The needs of those seeking breast cancer information and support from a cancer patient advocacy organization in Brazil
de Camargo Barros LH, Siqueira ACA, Kruse M, dos Santos AM, Neumann LTV. Instituto Oncoguia, São Paulo, Brazil.
   
  Psychosocial, QOL, and Educational Aspects: Social and Education Issues - Cost-Effectiveness
P3-16-01 Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
Veenstra DL, Hendrix N, Dolan CM, Fisher K, Lalla D, Hill N, Moy B. University of Washington, Seattle, WA; Department of Global Health & Population, T.H. Chan School of Public Health, Harvard University, Boston, MA; CMD Consulting, Sandy, UT; Puma Biotechnology, South San Francisco, CA; Puma Biotechnology, South San Francisco, WA; Massachusetts General Hospital Cancer Center, Boston, MA.
P3-16-02 Enhancing impact and efficiency of financial support for cancer through use of AI: A nascent initiative of Indian cancer society
Vora T, Khanna N, Gokarn A, Rawat A, Ramarajan N, Srivastava G, Thorat U. Princess Margaret Cancer Centre, Toronto, ON, Canada; Tata Memorial Hospital, Mumbai, India; Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India; Indian Cancer Society, Cancer Cure Fund, Mumbai, India; National Cancer Grid, Oncology, Mumbai, India.
P3-16-03 Clinical and pharmacoeconomic analyses of CDK4/6 inhibitors use in stage IV breast cancer females in the state of Qatar: A comparative retrospective observational study with cost effectiveness and cost utility analyses
Al-Ziftawi NH, Elazzazy S, Alam MF, Shafie AA, Hamad A, Bujassoum S, Ibrahim MI. Qatar University, QU Health, Doha, Qatar; Hamad General Corporation, National Center for Cancer Care and Research, Doha, Qatar; Universiti Sains Malaysia, School of Pharmaceutical Sciences, Malaysa, Malaysia.
P3-16-04 Estimation of willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A): The main study findings
Iwatani T, Hara F, Shien T, Takahashi M, Masuda N, Sagara Y, Sasaki K, Mizusawa J, Fukuda H, Shiroiwa T, Iwata H. Department of Breast Surgery, National Cancer Center Hospital East, Kashiwa, Japan; Department of Breast Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan; Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan; Department of Breast Surgery, Sagara Hospital, Kagoshima, Japan; Japan Clinical Oncology Group (JCOG) Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan; Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health, Wako, Japan; Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
   
  Psychosocial, Quality of Life and Educational Aspects-Social and Education Issues: Education
P3-17-01 Metastatic breast cancer caregiver participation in a psychoeducational cancer support program: Results from the frankly speaking about cancer: Metastatic breast cancer evidence-based educational workshops
Saxton C, Fearnley K, Gonzalo MB, Schwartz C. Cancer Support Community, Washington, DC
P3-17-02 Knowledge is power: Designing an educational program to support black breast cancer patients
Rivers J, Tomlin T, Ahlum Hanson A, Ormerod C, Guglielmino JE. The Chrysalis Initiative, Philadelphia, PA; My Style Matters, Atlanta, GA; Living Beyond Breast Cancer, Bala Cynwyd, PA.
P3-17-03 Raising the level of cancer care around the world: The feasibility and perceived benefit of a virtual breast tumor board
Dempsey N, Chiec L, Lodder M, Shonkwiler E, Haines K, Mahtani R, Gradishar W, Buchholz T, O'Dea A, Wolmark N, Hurvitz S, O'Shaughnessy J, Jochelson M, Butler R, Mamounas E, Vicini F, Pegram M, Shah C, King T, O'Regan R, Morrow M, Jahanzeb M. Lynn Cancer Institute, Boca Raton, FL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Private Practice, Kansas City, MO; University of Kansas Cancer Center, Kansas City, KS; Florida Precision Oncology, Boca Raton, FL; Sylvester Comprehensive Cancer Center of University of Miami, Deerfield Beach, FL; Scripps MD Anderson, Houston, TX; University of Kansas, Kansas City, KS; NSABP Foundation, Inc, Pittsburgh, PA; UCLA, Los Angeles, CA; Baylor University Medical Center, Dallas, TX; Memorial Sloane Kettering, Evelyn H. Lauder Breast Center, New York, NY; Yale University, New Haven, CT; University of Florida Health Cancer Center Orlando, Orlando, FL; Genesis Care, Farmington Hills, MI; Stanford University, Palo Alto, CA; Cleveland Clinic, Cleveland, OH; Dana-Farber/Brigham and Women’s Cancer Center , Boston, MA; University of Rochester, Rochester, NY; Memorial Sloan Kettering Cancer Center, New York, NY.
P3-17-04 Perceived value of patient education among breast cancer patients: A moderator of the antecedents and consequences of patients’ satisfaction
Berger V, Beaumont N, Labbe B, Lombart C. Institut de Cancérologie de l'Ouest, Angers, France; Audencia Business School, Nantes, France.
P3-17-05 Physicians’ attitudes and perceived barriers to adherence to national breast cancer clinical practice guidelines (BCCPG) in Mexico
Martinez-Cannon BA, Soto-Perez-de-Celis E, Erazo Valle-Solis AA, Arce Salinas C, Bargallo Rocha E, Bautista Piña V, Cervantes Sanchez MG, Flores Balcazar CH, Lara Tamburrino MdC, Lluch Hernandez A, Maffuz Aziz A, Perez Sanchez VM, Poitevin Chacon A, Salas Gonzalez E, Torrecillas Torres L, Valero V, Villaseñor Navarro Y, Cardenas Sanchez J. Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubian, Ciudad de Mexico, Mexico; Centro Medico Nacional 20 de Noviembre, Ciudad de Mexico, Mexico; Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico; Instituto de Enfermedades de la Mama, Ciudad de Mexico, Mexico; Grupo CT Scanner de Mexico, Ciudad de Mexico, Mexico; Hospital Clinico, Valencia, Spain; Centro Medico ABC, Ciudad de Mexico, Mexico; Medica Sur, Ciudad de Mexico, Mexico; Centro Medico Nacional de Occidente, Guadalajara, Mexico; M.D. Anderson Cancer Center, Houston, TX; Centro Medico de Colima, Colima, Mexico.
P3-17-06 Telephone triaging during the 1st wave of the COVID 19 Pandemic: Outcomes and proposed pathway for managing patients referred for breast pain
Jain U, Coombe R, Bitsakou G, Kothari A. Guys and St Thomas' NHS foundation Trust, London, UK, London, United Kingdom.
   
  Treatment - Surgery and Radiotherapy: Breast Conservation
P3-18-01 Assessment of DCISionRT for guiding radiotherapy of DCIS in Sweden
Wärrnberg F, Wadsten C, Karakatsanis A, Olofsson Bagge R, Holmberg E, Karlsson P, Lindman H, Whitworth PW, Sawyer E, Shah C, Shivers S, Vicini F, Mann BG, Bremer T. Dept. of Surgery, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Deparment of Surgery, Sumdsvall Hospital, Umeå University, Umeå, Sweden; Dept. of Surgical Sciences, Uppsala University, Uppsala, Sweden; Dept of Surgery, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Dept. of Oncology, Sahlgrenska Academy at Gothenburg Univeristy, Gothenburg, Sweden; Dept. of Oncologu, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden; Dept. of Oncology, Uppsala University, Gothenburg, Sweden; Nashville Breast Centre, Nashville, TN; Guys Cancer Centre, Kings College, London, United Kingdom; Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH; PreludeDx, Laguna Hills, CA; GenesisCare, Royal Oak, Royal Oak, MI; Department of Surgery, University of Melbourne, Melbourne, Australia; Prelude Dx, Laguna Hills, CA.
P3-18-02 Breast conservation plus radiotherapy provides superior survival benefit than mastectomy in triple negative breast cancer: A propensity matched national cancer database analysis
Cao L, Towe CW, Miller ME, Montero AJ, Shenk R. University Hospitals Cleveland Medical Center, Cleveland, OH.
P3-18-03 Long-term outcomes for breast conservation plus radiotherapy versus mastectomy in early breast cancer after neoadjuvant systemic therapy: Results from the Swedish national breast cancer register (NKBC)
Wang K, Duinmeijer A, Matikas A, Altena R, Johansson H, Fredholm H, Foukakis T. Karolinska Institutet, Solna, Sweden.
P3-18-04 Evaluating de-escalation of breast radiation (DEBRA) following lumpectomy for breast conservative treatment of stage 1, hr+, HER2-, RS ≤18 breast cancer: NRG-BR007 a phase III trial
White J, Anderson SJ, Harris EER, Mamounas EP, Stover DG, Ganz PA, Jagsi R, Cecchini RS, Bergom C, Theberge V, El-Tamer M, Zellars RC, Shumway DA, Chen G-P, Julian TB, Wolmark N. NRG Oncology and Ohio State University Comprehensive Cancer Center, Columbus, OH; NRG Oncology and University of Pittsburgh, Pittsburgh, PA; NRG Oncology and University Hospitals Case Western Reserve University, Cleveland, OH; NRG Oncology and Orlando Health Cancer Institute, Orlando, FL; NRG Oncology and UCLA Jonsson Comprehensive Cancer Center, UCLA Fielding School of Public Health, Los Angeles, CA; NRG Oncology and University of Michigan, Ann Arbor, MI; NRG Oncology and Washington University School of Medicine, St. Louis, MO; CCTG and CHU de Quebec – Universite Laval, Quebec City, QC, Canada; Alliance and Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, New York, NY; ECOG-ACRIN and Indiana University, Indianapolis, IN; SWOG and Mayo Clinic, Rochester, MN; Medical College of Wisconsin, Milwaukee, WI; NRG Oncology and Allegheny Health Network Cancer Institute, Pittsburgh, PA.
P3-18-05 Impact of neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) on breast tumor downsizing for patients with HER2+ breast cancer - results from a single-arm clinical trial
Weiss A, Li T, Desai NV, Tung NM, Tayob N, King TA, Winer EP, Mittendorf EA, Waks AG. Brigham and Women's Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA.
P3-18-06 Satisfaction and physical wellbeing after breast conserving therapy: Clinical predictors and reference values using the BREAST-Q
Chu JJ, Nelson JA, Garcia P, Mehrara BJ, Pusic AL, Morrow M, Gemignani ML, Tadros AB. Memorial Sloan Kettering Cancer Center, New York, NY.
P3-18-07 Margin involvement in invasive breast cancer leads to increased distant recurrence after breast conservation: Systematic review
Bundred JR, Dodwell D, Cuttress R, Michael S, Stuart B, Holleczek B, Beckmann K, Dahlstrom J, Bundred NJ. Leeds University NHS Foundation Trust, Leeds, United Kingdom; Oxford University NHS Foundation Trust, Oxford, United Kingdom; Southampton University NHS Foundation Trust, Southampton, United Kingdom; Manchester University NHS Foundation Trust, Manchester, United Kingdom; University of Southampton, Soutahmpton, United Kingdom; Saarland Cancer Registry, Saarbruken, Germany; Cancer Research Institute, University of South Australia, Australia; University of South Australia, University of South Australia, Australia; University of Manchester, Manchester University NHS Trust, United Kingdom.
P3-18-08 Feasibility and safety of breast-conserving surgery in early-stage breast cancers during the first trimester of pregnancy
Fusco N, Blundo C, Giroda M, Sajjadi E, Venetis K, Leonardi MC, Vicini E, Despini L, Rossi CF, Runza L, Di Loreto E, Scarfone G, Guerini-Rocco E, Viale G, Veronesi P, Buonomo B, Peccatori FA, Galimberti VE. European Institute of Oncology (IEO), Milano, Italy; Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy.
P3-18-09 Refusal of breast surgery in breast cancer patients with clinical complete response (cCR) after neoadjuvant systemic therapy and vacuum-assisted biopsy (VAB) and sentinel lymph node biopsy (SLNB) confirmed pathological complete response (pCR). A first report of the prospective non-randomized trial results. NCT04293796
Krivorotko P, Yerechshenko S, Emelyanov A, Busko E, Bessonov A, Gukova V, Komyahov A, Zhiltsova E, Nikolaev K, Tabagua T, Gigolaeva L, Pesotsky R, Novikov S, Bryantseva Z, Artemyeva A, Smirnova V, Kushnarev V, Belyaev A, Semiglazova T, Semiglazov V. N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, Russian Federation.
P3-18-10 Current options and future perspectives for breast margin assessment in clinical practice
Javaid H, Marin I, Montalvan J, Healy L, Menegaz B, Hsu C, Silberfein E, Bonefas E, Carter SA, Thompson AM. Baylor College of Medicine, Houston, TX.
P3-18-11 Meeting the challenge of successful one-stage lumpectomy for DCIS
Feinberg JA, DiMaggio C, Pourkey N, Chun Kim J, Goodgal J, Guth A, Axelrod D, Schnabel F. NYU, New York, NY.
P3-18-12 Achieving negative margin after repeated attempts for lumpectomy does not nullify the risk of ipsilateral breast tumor recurrences
Cheun JH, Kim H-K, Lee H-B, Han W, Moon H-G. Seoul National University Hospital, Seoul, Republic of Korea.
P3-18-13 A cross-sectional study to investigate association between oncoplastic techniques and patient satisfaction who received breast-conserving surgery
Mitsueda R, Gen A, Fujiki Y, Gondo N, Sato M, Kawano J, Kuninaka K, Kanemitsu S, Teraoka M, Matsuyama Y, Baba S, Nomoto S, Sloan R, Rai Y, Sagara Y, Sagara Y. Sagara Hospital HAKUAIKAI Social Medical Corporation, Kagoshima City, Japan; Kagoshima University Graduate School of Medical Sciences, Kagoshima City, Japan.
P3-18-14 Assessment of quality of life and objective cosmetic outcome of breast conserving surgery with or without latissimus dorsi mini-flap in breast cancer
Kim J-i, Han Y, Lim C, Cheun J-H, Jung JG, Kim HK, Lee H-B, Moon H-G, Han W. Seoul National University College of Medicine, Seoul, Republic of Korea.
P3-18-15 Reliability and measurement error of breast volume calculation using 3D surface imagery
Fearn NR, Meybodi F, Kilbreath S, Dylke E, Llanos C, Stuart K. The University of Sydney, Sydney, Australia; Westmead Breast Cancer Institute, Sydney, Australia.
P3-18-16 Breast conserving surgery in BRCA-mutation carriers. A single Institution experience
Losurdo A, Gentile D, Zuradelli M, Sagona A, Barbieri E, Barile M, Bianchi P, Torrisi R, Gatzemeier W, Scorsetti M, Tinterri C, Santoro A. Istituto Clinico Humanitas, Humanitas Cancer Center, IRCCS, Rozzano (MI), Italy.
P3-18-17 Impact of change in margin negative guidelines for breast cancer on recurrence rates: Single institution audit
Murali-Nanavati SR, Nair N, Hawaldar R, Parmar V, Shet T, Siddique S, Vanmali V, Joshi S, Badwe R. Tata Memorial Hospital, Mumbai, India.
   
  Treatment - Surgery and Radiotherapy: Radiotherapy
P3-19-01 CANTO RT: The largest prospective multicenter cohort of early breast cancer patients treated with radiotherapy including full DICOM RT data
Sarrade T, Allodji R, Ghannam Y, Auzac G, Everhard S, Querel O, Kirova Y, Peignaux K, Guilbert P, Charra-Brunaud C, Blanchecotte J, Belshi R, Pasquier D, Racadot S, Bourgier C, Ducornet S, Gibon D, André F, De Vathaire F, Rivera S. Radiotherapy Department, Gustave Roussy, Villejuif, France; Gustave Roussy, Unit INSERM UMR U1018, Villejuif, France; UNICANCER, Paris, France; Institut Curie, Paris, France; Centre Georges-François Leclerc, Dijon, France; Institut Jean Godinot, Reims, France; Institut de Cancérologie de Lorraine, Vandoeuvre les Nancy, France; Institut de Cancérologie de L'ouest - Paul Papin, Angers, France; Institut Curie, Saint Cloud, France; Centre Oscar Lambret, Lille, France; Centre Léon Bérard, Lyon, France; ICM, Montpellier, France; Aquilab, Loos, France; Gustave Roussy, Villejuif, France; Radiotherapy Department, Molecular Radiotherapy and Therapeutic Innovation Unit INSERM UMR 1030 - Université Paris-Saclay, Gustave Roussy, Villejuif, France.
P3-19-02 Should deep inspiration breath hold scans be standardly acquired for right-sided breast/chestwall and regional nodal irradiation?.
Jhawar SR, Lindsey K, Kuhn K, Tedrick K, Zoller I, Taylor W, Cochran E, Healy E, Beyer S, White J, Bazan JG. The Ohio State University, Columbus, OH.
P3-19-03 Preliminary results of a feasibility study assessing radiation response with MRI/CT directed preoperative accelerated partial breast irradiation in the prone position for hormone responsive early stage breast cancer
Beyer S, Smith T, Sekhon A, Bazan J, Jhawar S, Healy E, Wei L, Yildiz V, Mohamed M, Knopp M, White J. Stefanie Spielman Comprehensive Breast Center at The Ohio State University, Columbus, OH; Center for Biostatistics at The Ohio State University, Columbus, OH; Department of Radiology at The Ohio State University, Columbus, OH.
P3-19-04 Minimal increases in tumor infiltrating lymphocytes despite excellent tumor responses after pre-operative accelerated partial breast irradiation in early stage ER+ breast cancer patients
Currey A, Jorns JM, Desai N, Kelly TR, Bovi J, Kong AL, Wadhwa A, Paulson E, Bergom C. Medical College of Wisconsin, Milwaukee, WI; ThedaCare Regional Cancer Center, Appleton, WI; Washington University, St. Louis, MO.
P3-19-05 Genomic machine learning model predicts radiation therapy benefit in early-stage breast cancer patients with high accuracy
Badal K, Foster J, Haraksingh R, John M. The University of the West Indies, St Augustine, Trinidad and Tobago.
P3-19-06 Radiation toxicity in ATM mutation carriers with breast cancer
Lee B, Chan E, Cheng PTM, Tyldesley S, Schrader KA, Sun S. BC Cancer, Vancouver, BC, Canada.
P3-19-07 Hypofractionated and conventional whole-breast radiotherapy for breast cancer patients: Financial risk and expenditures in the U.S. 2008-2017
Saulsberry L, Liao C, Huo D. The University of Chicago, Chicago, IL.
P3-19-08 Breast cancer related lymphedema in patients undergoing RNI: Is the axillary lateral vessel thoracic junction an organ-at-risk?
Healy E, Jhawar S, Beyer S, White JR, Bazan JG. James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH.
P3-19-09 Impact of intraoperative radiation therapy and external beam radiation therapy on non-breast cancer mortality in early-stage breast cancer
Bazan JG, Fisher J, Jhawar S, Healy E, Beyer S, White JR. James Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH.
P3-19-10 Subcutaneous layer dosimetry of the breast and chest wall at clinical beam energies without bolus: A Monte Carlo and analytical anisotropic algorithm (AAA) calculation study
Narinesingh E, Nichol A, Bergman A, Popescu T. BC Cancer, Vancouver, BC, Canada.
P3-19-11 Long-term outcomes of primary and secondary angiosarcomas of the breast: A 20-year single-center experience
Tolba M, Di Lalla V, Khosrow-Khavar F, Baig A, Freeman C, Panet-Raymond V. Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Pathology, McGill University Health Centre, Montreal, QC, Canada.
P3-19-12 Impact of endocrine therapy (ET) noncompliance following intra-operative radiation therapy (IORT) in treatment of early-stage breast cancer patients (pts) enrolled in the ExBRT trial
Schwartzberg B, Syed A, Cohen R, Dooley W, Farha M, Jones V, Hodge W. Schwartzberg Center for Minimally Invasive Breast Surgery, Santa Rosa, CA; MemorialCare Health System, Long Beach, CA; Inova Health System, Schar Cancer Institute, Fairfax, VA; University of Oklahoma Breast Institute, Oklahoma City, OK; Medstar Good Samaritan Hospital, Baltimore, MD; City of Hope National Medical Center, Duarte, CA; Advent Health Florida Hospital, Orlando, FL.
P3-19-13 Radiation oncology treatment planning in breast cancer patients undergoing lumpectomy with and without oncoplastic reconstruction
Lue BK-H, Kakadiaris E, Alluri P. UT Southwestern Medical Center, Dallas, TX.
P3-19-14 Development of simplified auto-segmentable functional cardiac atlas
Loap P, De Marzi L, Kirov K, Servois V, Fourquet A, Khoubeyb A, Kirova Y. Institut Curie, Paris, France.
P3-19-15 Prognostic impact of radiation therapy in mucinous carcinoma of the breast
Chevli N, Wang K, Haque W, Schwartz MR, Nangia J, Sasaki J, Farach AM, Hatch SS, Butler EB, Teh BS. Department of Radiation Oncology, The University of Texas Medical Branch at Galveston, Galveston, TX; Department of Radiation Oncology, University of Arkansas, Little Rock, AR; Department of Radiation Oncology, Houston Methodist Hospital, Houston, TX; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX; Department of Medical Oncology, Baylor College of Medicine, Houston, TX; Breast Surgery, Texas Breast Specialists, Houston, TX; Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX.
P3-19-16 Impact of targeted intraoperative (TARGIT-IORT) tumor bed boost during breast conserving surgery for early breast cancer on breast cancer associated and non-breast cancer associated mortality and morbidity
Kolberg H-C, Gutberlet S, Vaidya JS, Krajewska M, Lövey G, Hoffmann O, Stephanou M, Kolberg-Liedtke C. Marienhospital Bottrop, Bottrop, Germany; Alfried-Krupp-Krankenhaus, Essen, Germany; University College London, London, United Kingdom; Charité - Universitätsmedizin Berlin, Berlin, Germany; BORAD, Bottrop, Germany; Universitätsfrauenklinik Essen, Essen, Germany.
P3-19-17 Radiation of the low axilla in the prone position
Doss V, Healy E, Beyer S, Jhawar SR, Bazan JG, White J. The Ohio State University, Columbus, OH.
P3-19-18 Feasibility and short term toxicity of a consecutively delivered 5-fraction stereotactic body radiotherapy in early stage breast cancer patients receiving accelerated partial breast irradiation
Liu Y, Veale C, Hablitz D, Krontiras H, Dobelbower MC, Lancaster R, Bredel M, Parker C, Keene K, Thomas E, Boggs DH. University of Alabama at Birmingham, Birmingham, AL.
P3-19-19 Intraoperative Radiation Therapy (IORT) : A large integrated healthcare system’s approach and outcomes
Tang A, Kelly J, Cureton E, Svahn J, Thomas E, Lyon L, Shim V. Department of Surgery, University of California, San Francisco, Oakland, CA; The Permanente Medicine, Radiation Oncology, Oakland, CA; The Permanente Medicine, Surgery, Oakland, CA; The Permanente Medicine, Medical Oncology, Oakland, CA; The Permanente Medicine, Division of Research, Oakland, CA.
P3-19-20 Are traditional indications for radiation therapy appropriate for small cell carcinoma of the breast: An NCDB outcomes analysis and treatment utilization report
Cantrell JN, Pius P, Acharya P, Vesely S, Henson C, Algan O. University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Dept of Radiation Oncology, Oklahoma City, OK; University of Oklahoma Health Sciences Center, Hudson College of Public Health, Dept of Epidemiology and Biostatistics, Oklahoma City, OK.
P3-19-21 Semi-lateral decubitus position using Alexandria left breast board-16. A prospective study regarding dose distribution and reproduciblity
Emam OS, Abouegylah M, Elsaka R, Munir A, Aziz F, Ismail AA, Elsaid AA. Faculty of Medicine, Alexandria University, Alexandria, Egypt.
P3-19-22 Clinical and cosmetic outcomes of adjuvant stereotactic partial breast irradiation using the GammaPod
Paulosky K, Ruff S, Becker SJ, Guerrero M, McAvoy S, Nichols EM. Univeristy of Maryland School of Medicine, Baltimore, MD.
P3-19-23 Radiation-induced sarcomas of the breast: A 20-year single-centre experience
Di Lalla V, Tolba M, Khosrow-Khavar F, Baig A, Freeman C, Panet-Raymond V. Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada; Gerald Bronfman Department of Oncology, McGill University, Montreal, QC, Canada; Pathology, McGill University Health Centre, Montreal, QC, Canada.
P3-19-24 Long-term follow-up results of intensity modulated radiotherapy in early-stage breast cancer patients
Zolcsák Z, Loap P, Fourquet A, Arsene Henry A, Landherr L, Hamar P, Kirova Y. Uzsoki Hospital, Budapest, Hungary; Institut Curie, Paris, France; Semmelweis University, Budapest, Hungary.
P3-19-25 ICE3 trial - Radiation following cryoablation for low-risk breast tumors: Assessment of safety and variables that effect referral
Dietz JR, Fine RE, Boolbol SK, Haziza R. Allegheny Health Network, Pittsburgh, PA; West Cancer Center, Germantown, TN; Mount Sinai Beth Israel, New York, NY; Masaryk University, Brno, Czech Republic.
P3-19-26 The impact of post-mastectomy radiotherapy on the survival of breast cancer patients aged 70 years or older: A study based on SEER database
Lin J, Luo S, Zhang J, Song C. Fujian Medical University Union Hospital, Fuzhou, China.
P3-19-27 Prognostic impact of postmastectomy radiation therapy in breast cancer patients with T1, 2 and 1-3 lymph nodes from Japan Breast Cancer Registry
Yamada A, Hayashi N, Kumamaru H, Nagahashi M, Usune S, Miyata H, Ishikawa T, Narui K, Endo I, Imoto S, Ohno S, Jinno H. Yokohama City University Hospital, Yokohama, Japan; St. Luke's International Hospital, Tokyo, Japan; The University of Tokyo, Tokyo, Japan; Hyogo Collage of Medicine Hospital, Hyogo, Japan; Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center, Yokohama, Japan; Kyorin University Hospital, Tokyo, Japan; The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; Teikyo University School of Medicine, Tokyo, Japan.
P3-19-28

The impact of PM 2.5 on the radiation-induced pneumonitis in patients with breast cancer


Kim DY, Kim IA, Jang BS. Seoul National University Hospital, Seoul, Korea, Republic of Seoul National University Bundang Hospital, Seongnamsi, Kyeonggido, Korea, Republic of
P3-19-29 Polygenic risk scores predict toxicities in racially diverse breast cancer patients following radiotherapy
Torres MA, Liu T, Zhou B, Yang X, Brown G, Green I, Lin J, Miller AH, Yang J. Winship Cancer Institute of Emory University, Atlanta, GA.
   
  Treatment - Surgery and Radiotherapy: Surgery
P3-20-01 Increased distant recurrence following margin involvement in early invasive breast cancer in two large UK cohorts
Bundred NJ, Michael S, Broggio J, Armstrong A, Martin G, Absar M, Ooi J. Manchester University NHS Foundation Trust, Manchester, United Kingdom; Public Health England, Birmingham, United Kingdom; The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom; Countess of Chester NHS trust, Chester, United Kingdom.
P3-20-02 The association of clinicopathological variables and patient´s preference with surgical decision-making for early breast cancer
Söderberg E, Sund M, Wärnberg F, Holmberg L, Nilsson G, Garmo H, Blomqvist C, Wadsten C. Department of Surgery, Sundsvall Hospital, Umeå University, Umeå, Sweden; Department of Surgery and Perioperative Sciences, Umeå University, Umeå, Sweden; Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden; Translational Oncology & Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, Kings College London, London, United Kingdom; Department of Immunology, Genetics and Pathology, Section of Experimental and Clinical Oncology, Uppsala University, Uppsala, Sweden; Regional Cancer Centre, Uppsala University/ University Hospital, Uppsala, Sweden; Department of Oncology, Örebro University, University Hospital, Örebro, Sweden; Department of Surgery and Perioperative Sciences, Umeå University, Sundsvall Hospital, Umeå University, Umeå, Sweden.
P3-20-03 Breast-conserving surgery improves the outcomes of disease-free survival and overall survival in young women with breast cancer (≤35 years): A retrospective study based on surgical options
Li P, Li L, Xue J, Wu J. Fudan University Shanghai Cancer Center, Shanghai, China; The Second Xiangya Hospital of Cental South University, Changsha, China.
P3-20-04 High-resolution 18F-FDG PET-CT for peri-operative margin assessment in early-stage breast cancer: Results of an ongoing clinical study
Göker M. University Hospital Gent, Gent, Belgium.
P3-20-05 Trends of axillary treatment in sentinel node-positive breast cancer patients undergoing amputation
Verreck EEF, van Steenhoven J, Kuijer A, van Maaren M, Siesling S, van Dalen T. Diakonessenhuis, Utrecht, Netherlands; IKNL, Utrecht, Netherlands.
P3-20-06 Magseed/magtrace-guided surgery in breast cancer- an institutional perspective
Montalvan J, Healy L, Javaid H, Marin I, Menegaz B, Hsu C, Silberfein E, Bonefas E, Carter S, Thompson A. Baylor College of Medicine, Houston, TX.
P3-20-07 Uncontrolled hypertension and the development of lymphedema after breast cancer surgery
Weisberg E, Assad H, Choi-Kim L, DeMeere T, Jang H, Chen W, Kosir MA. Wayne State University, Detroit, MI; Wayne State University, Department of Oncology, Detroit, MI; Wayne State University, Department of Surgery, Detroit, MI; Detroit Medical Center, Detroit, MI; Wayne State University/Karmanos Cancer Institute, Detroit, MI.
P3-20-08 Does contralateral prophylactic mastectomy improve survival in triple negative breast cancer?
Fasano GA, Bayard S, Chen Y, Marti J, Simmons R, Swistel A, Bensenhaver J, Nathanson SD, Petersen L, Proctor E, Davis M, Newman L. Weill Cornell Medicine, New York, NY; Henry Ford Health System, Detroit, MI.
P3-20-09 Surgery vs radiation therapy as the first stage treatment in patients with locally advanced breast cancer with incomplete clinical response
Petrovsky A, Amosova V, Trofimova O, Frolova M. N.N.Blokhin National Cancer Research Center, Moscow, Russian Federation.
P3-20-10 Local recurrences after mammary adenectomy with clear retroareolar margin for the treatment of early infiltrating breast carcinomas
Heinzen RN, de Barros2 ACSD, Jacomo A, Cinquini M. CEOF, Florianopolis, Brazil; USP, Sao Paulo, Brazil.
   
  Treatment - Surgery and Radiotherapy: Reconstruction
P3-21-01 A higher locoregional recurrence rate of nipple areolar complex sparing mastectomy with immediate implant reconstruction
You JY, Lee E-G, Park SJ, Kim BN, Lee S, Lee ES, Jung S-Y, Kwon Y, Kim YJ, Lee CW, Kim TH. Korea University, Seoul, Republic of Korea; National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea; Wonkwang University, Sanbon, Gyeonggi-do, Republic of Kora.
P3-21-02 Robotic nipple sparing mastectomy in the management of breast cancer and prophylactic surgeries with SP system
Lee SB, Han HH, Kim J, Ko B. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
P3-21-03 Timing of post-mastectomy radiation therapy and autologous reconstruction outcomes: A retrospective review
Barnes L, Martins D, Piper M. University of California, San Francisco, San Francisco, CA.
   
  Treatment - Research Resources: Patient Resources
P3-22-01 The past and present of breast cancer resources: A re-evaluation of the quality of online resources in breast cancer after eight years
Killow V, Ingledew P, Lin J. BC Cancer Agency, Vancouver, BC, Canada; University of Calgary, Calgary, AB, Canada.
   
  Treatment - Treatment: Other
P3-23-01 Antibody responses after SARS-CoV-2 mRNA vaccination in breast cancer patients
Chumsri S, Advani PP, Pai TS, Li Z, Acampora M, Reynolds GA, Moreno-Aspitia A, Marquez CP, Knutson KL. Mayo Clinic, Jacksonville, FL.
P3-23-02 Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer receiving CDK 4/6 inhibitors
Denault E, Nakajima E, Naranbhai V, Balazs A, Mortensen L, Niehoff E, Barabell C, Hutchinson JA, Wander SA, Rosenstock AS, Ellisen LW, Moy B, Isakoff SJ, Gainor JF, Iafrate AJ, Bardia A, Spring LM. Massachusetts General Hospital, Boston, MA.
P3-23-03 Use of taxane-containing regimens during pregnancy for the treatment of breast cancer: A systematic review
Ferrigno AS, Becerril-Gaitan A, Vaca-Cartagena BF, Azim, Jr. HA, Villarreal-Garza C. Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico.
P3-23-04 A comprehensive, multidisciplinary approach to breast cancer treatment during the COVID-19 pandemic improves time to treatment
Orucevic A, Hutson R, Heidel R, Lloyd J, Morin-Ducote G, Lauro C, Perkins E, Panella T, Duncan L, VanMeter S, Bell J. The University of Tennessee Medical Center, Knoxville, TN.
P3-23-05 Evaluation of CDK 4/6 inhibitor practice patterns and institutional versus national adherence to palbociclib laboratory monitoring in breast cancer patients
Taraba J, Swarna K, Golbach A, Sangaralingham L, Ruddy K, Mara K, Smith M, Haddad T, Giridhar K. Mayo Clinic, Rochester, MN; The University of Kansas Health System, Kansas City, KS.
P3-23-06 Withdrawn
P3-23-07 Radiation induced angiosarcoma of the breast: Chemotherapy for radiation induced angiosarcoma of the breast - An individual participant data meta-analysis of Japanese population
Takehara Y, Matsuda N, Kobayashi D, Yoshida A, Takei J, Tsunoda H, Kanomata N, Yamauchi H, Hayashi N. Department of Breast Surgical Oncology, St. Luke's International Hospital, Chuo-Ku, Tokyo, Japan; Graduate School of Public Health, St. Luke's International University, Chuo-Ku, Tokyo, Japan; Department of Radiology, St. Luke's International Hospital, Chuo-Ku, Tokyo, Japan; Department of Pathology, St. Luke's International Hospital, Chuo-Ku, Tokyo, Japan.
   
  Rescheduled Posters
P5-14-12 Health literacy among long term breast cancer survivors; exploring associated factors in a nation-wide sample
Vandraas KF, Reinertsen KV, Kiserud CE, Bøhn SK, Lie HC. Oslo University Hospital, Oslo, Norway; University of Oslo, Oslo, Norway.